Drugs · Brain health technique
GLP-1 Receptor Agonists
Evidence grade: Context Dependent
A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation. Includes semaglutide (Ozempic®, Wegovy®, Rybelsus®), liraglutide (Victoza®, Saxenda®), and tirzepatide (Mounjaro®, Zepbound®).
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Metabolic & Vascular Optimization Drugs
- Evidence grade
- Context Dependent
- Strength of evidence
- Medium
How to practice GLP-1 Receptor Agonists
Prescribed for type 2 diabetes, obesity, or metabolic syndrome. Typical dosing: once-weekly injection (semaglutide or tirzepatide) or daily injection (liraglutide). Combine with diet and activity modification. Common side effects: nausea, GI upset, constipation. Avoid in history of medullary thyroid cancer or pancreatitis. Not yet approved for cognitive prevention.
The evidence behind GLP-1 Receptor Agonists
Large RCTs confirm strong cardiometabolic benefits - weight loss, improved glucose control, and reduced cardiovascular events. While early studies suggested slower cognitive decline via enhanced insulin signaling and mitochondrial function, the large Phase 3 EVOKE trials did not meet their primary endpoint of slowing cognitive and functional decline in patients with established Alzheimer’s disease. Mechanism: The intervention restores neuronal glucose utilization and dampens inflammatory pathways, yet this biological effect did not translate to clinical benefit in later disease stages over the trial period. Evidence remains strong for metabolic and vascular protection, which is crucial for prevention, but is now lower for direct cognitive impact once the disease is established.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.